Reduced BRMS1L in breast cancer tissues are associated with metastasis and poor patient survival through epigenetic silencing of FZD10, a receptor for Wnt signalling, through histone deacetylase 1 (HDAC1) recruitment and histone H3K9 deacetylation at the promoter, followed by the inhibition of the aberrant activation of WNT3-FZD10-β-catenin signalling. Here, WNT3 is linked to breast carcinoma.